University of Maryland Greenebaum Cancer Center
University of Maryland Greenebaum Cancer Center
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of 500mg of Fulvestrant | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-05-22 | NCT00585507 | |
| First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, adenoma, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, epithelial neoplasm, hormone-resistant breast carcinoma, lung disorder, lung neoplasm, mesothelial neoplasm, mesothelioma, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 1 | 2022-11-28 | NCT05627960 |